Oculis Holding AG Reports Q4 and Full Year 2024 Financial Results and Business Updates
ZUG, Switzerland, March 11, 2025 – Oculis Holding AG, a leading biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, recently released its financial results for the quarter and full year ended December 31, 2024. In addition, the Company provided an overview of its recent progress.
Financial Highlights
For the full year 2024, Oculis reported a net loss of CHF 125.5 million ($133.6 million), compared to a net loss of CHF 128.2 million ($135.5 million) in the previous year. The Company’s research and development expenses decreased by 10.6% to CHF 113.6 million ($120.9 million) from CHF 127.2 million ($136.2 million) in 2023. General and administrative expenses were CHF 11.9 million ($12.7 million), a 4.8% decrease from CHF 12.5 million ($13.4 million) in 2023.
Business Updates
During the fourth quarter of 2024, Oculis achieved several significant milestones:
- OCU310: The Company completed enrollment in the Phase 3 clinical trial for OCU310, its lead product candidate for the treatment of ocular rosacea. Topline data is expected in the second half of 2025.
- OCU400: Oculis initiated a Phase 2 clinical trial for OCU400, a potential treatment for dry age-related macular degeneration (AMD).
- Partnerships: The Company entered into a collaboration with Sanofi to develop and commercialize OCU310 and OCU400 in Europe, the Middle East, Africa, and selected emerging markets.
Impact on Individuals
These developments could lead to potential advancements in the treatment of various ophthalmic and neuro-ophthalmic diseases. For individuals suffering from ocular rosacea, the successful completion of the Phase 3 clinical trial for OCU310 could mean the availability of a new, effective treatment option in the near future. Additionally, the initiation of a Phase 2 clinical trial for OCU400 could pave the way for new treatments for dry AMD, a condition that affects millions of individuals worldwide.
Global Impact
The progress made by Oculis could significantly impact the global healthcare landscape, particularly in the ophthalmology sector. The successful development and commercialization of OCU310 and OCU400, along with potential collaborations and partnerships, could lead to improved patient outcomes, increased access to innovative treatments, and potential cost savings for healthcare systems.
Conclusion
Oculis Holding AG’s Q4 and full-year 2024 financial results and business updates showcase the Company’s continued commitment to addressing unmet medical needs in the ophthalmic and neuro-ophthalmic disease space. With the successful completion of a Phase 3 clinical trial for OCU310 and the initiation of a Phase 2 clinical trial for OCU400, Oculis is poised to make a significant impact on the lives of individuals suffering from various ophthalmic conditions and contribute to the global healthcare landscape.
